Financial reports
10-K
2023 FY
Annual report
14 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
31 Mar 22
10-Q
2021 Q3
Quarterly report
15 Nov 21
Current reports
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
29 Mar 24
8-K
Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
15 Mar 24
8-K
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds
14 Feb 24
8-K
Other Events
29 Dec 23
8-K
Other Events
19 Dec 23
8-K
Ensysce Biosciences Announces Completion of $1.7 Million Convertible Note Financing
29 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
17 Nov 23
8-K
Ensysce Biosciences Reports Third Quarter 2023 Financial Results
9 Nov 23
8-K
Ensysce Biosciences Secures $1.7 Million Convertible Note Financing
24 Oct 23
8-K
Submission of Matters to a Vote of Security Holders
28 Aug 23
Registration and prospectus
S-1/A
IPO registration (amended)
26 Mar 24
D
Exempt offering of security
20 Feb 24
424B3
Prospectus supplement
15 Feb 24
424B3
Prospectus supplement
14 Feb 24
S-1
IPO registration
16 Jan 24
RW
Registration withdrawal request
30 Nov 23
S-1/A
IPO registration (amended)
17 Nov 23
S-1
IPO registration
9 Nov 23
S-8
Registration of securities for employees
19 Oct 23
POS EX
Additional exhibits for listing
17 May 23
Proxies
DEFA14A
Additional proxy soliciting materials
19 Dec 23
DEFA14A
Additional proxy soliciting materials
9 Nov 23
DEF 14A
Definitive proxy
9 Nov 23
PRE 14A
Preliminary proxy
30 Oct 23
DEFA14A
Additional proxy soliciting materials
13 Jul 23
DEF 14A
Definitive proxy
13 Jul 23
DEF 14A
Definitive proxy
23 Feb 23
PRE 14A
Preliminary proxy
13 Feb 23
DEF 14A
Definitive proxy
29 Jul 22
DEFA14A
Additional proxy soliciting materials
29 Jul 22
Other
EFFECT
Notice of effectiveness
8 Apr 24
EFFECT
Notice of effectiveness
22 Nov 23
CORRESP
Correspondence with SEC
20 Nov 23
UPLOAD
Letter from SEC
17 Nov 23
EFFECT
Notice of effectiveness
10 May 23
CORRESP
Correspondence with SEC
9 May 23
CORRESP
Correspondence with SEC
9 May 23
UPLOAD
Letter from SEC
4 May 23
EFFECT
Notice of effectiveness
18 Jan 23
CORRESP
Correspondence with SEC
13 Jan 23
Ownership
SC 13G/A
Lincoln Park Capital Fund, LLC
14 Feb 24
SC 13D/A
GOWER BOB G
18 Jul 23
4
BOB G GOWER
6 Mar 23
4
BOB G GOWER
2 Mar 23
SC 13G/A
HG Vora Capital Management, LLC
14 Feb 23
SC 13G/A
CVI Investments, Inc.
14 Feb 23
SC 13G
Lincoln Park Capital Fund, LLC
7 Feb 23
4
BOB G GOWER
1 Feb 23
SC 13G
CVI Investments, Inc.
16 Dec 22
SC 13D/A
Silvers Daniel B.
7 Jul 22